X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (44) 44
humans (42) 42
oncology (26) 26
chemotherapy (25) 25
male (25) 25
middle aged (21) 21
radiotherapy (21) 21
female (20) 20
aged (19) 19
cancer (18) 18
antineoplastic combined chemotherapy protocols - therapeutic use (17) 17
pancreatic cancer (17) 17
treatment outcome (16) 16
adult (15) 15
radiation-therapy (15) 15
prognosis (12) 12
adenocarcinoma (11) 11
care and treatment (11) 11
combined modality therapy (11) 11
hematology, oncology and palliative medicine (11) 11
deoxycytidine - analogs & derivatives (10) 10
pancreatic neoplasms - pathology (10) 10
disease-free survival (9) 9
clinical trials (8) 8
gemcitabine (8) 8
non-hodgkins-lymphoma (8) 8
pancreatic neoplasms - therapy (8) 8
radiology, nuclear medicine & medical imaging (8) 8
surgery (8) 8
adenocarcinoma - pathology (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
carcinoma (7) 7
gastroenterology & hepatology (7) 7
gliomas (7) 7
hematology (7) 7
pancreatic neoplasms - drug therapy (7) 7
pancreatic neoplasms - mortality (7) 7
retrospective studies (7) 7
adenocarcinoma - therapy (6) 6
analysis (6) 6
central nervous system neoplasms - therapy (6) 6
chemoradiotherapy (6) 6
chemotherapy, adjuvant (6) 6
health aspects (6) 6
patients (6) 6
prospective studies (6) 6
salvage therapy (6) 6
survival (6) 6
survival analysis (6) 6
adenocarcinoma - drug therapy (5) 5
adenocarcinoma - radiotherapy (5) 5
adolescent (5) 5
antimetabolites, antineoplastic - therapeutic use (5) 5
brain neoplasms - drug therapy (5) 5
clinical trials as topic (5) 5
curative resection (5) 5
deoxycytidine - therapeutic use (5) 5
follow-up studies (5) 5
methotrexate (5) 5
methotrexate - therapeutic use (5) 5
pharmacology & pharmacy (5) 5
phase-iii trial (5) 5
therapy (5) 5
adenocarcinoma - mortality (4) 4
adenocarcinoma - surgery (4) 4
aged, 80 and over (4) 4
cell lung-cancer (4) 4
central nervous system (4) 4
central nervous system neoplasms - drug therapy (4) 4
central-nervous-system (4) 4
clinical study (4) 4
conformal radiotherapy (4) 4
cooperative-oncology-group (4) 4
deoxycytidine - administration & dosage (4) 4
diagnosis (4) 4
feasibility studies (4) 4
lymphoma - therapy (4) 4
medical research (4) 4
neoadjuvant therapy (4) 4
neoplasm staging (4) 4
pancreatic neoplasms - surgery (4) 4
primary cns lymphoma (4) 4
prostatic neoplasms - radiotherapy (4) 4
radiation therapy (4) 4
radiotherapy, adjuvant (4) 4
randomized controlled trials as topic (4) 4
survival rate (4) 4
trial (4) 4
1st-line treatment (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
brain neoplasms - mortality (3) 3
brain neoplasms - radiotherapy (3) 3
cancer therapies (3) 3
central nervous system neoplasms - diagnosis (3) 3
central nervous system neoplasms - mortality (3) 3
central nervous system neoplasms - radiotherapy (3) 3
chemoradiotherapy - methods (3) 3
cisplatin - administration & dosage (3) 3
cytarabine - therapeutic use (3) 3
disease progression (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 11, pp. 1521 - 1532
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9700, pp. 1512 - 1520
Summary Background Chemotherapy with high-dose methotrexate is the conventional approach to treat primary CNS lymphomas, but superiority of polychemotherapy... 
Internal Medicine | DEFERRED RADIOTHERAPY | MEDICINE, GENERAL & INTERNAL | B-CELL LYMPHOMA | INTERNATIONAL WORKSHOP | RESPONSE CRITERIA | EUROPEAN ORGANIZATION | CONSOLIDATING RADIOTHERAPY | NON-HODGKINS-LYMPHOMA | INITIAL TREATMENT | CENTRAL-NERVOUS-SYSTEM | CEREBROSPINAL-FLUID | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Methotrexate - therapeutic use | Lymphoma, Non-Hodgkin - radiotherapy | Cranial Irradiation - methods | Central Nervous System Neoplasms - radiotherapy | Adult | Lymphoma, Non-Hodgkin - drug therapy | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | Combined Modality Therapy | Remission Induction | Methotrexate - adverse effects | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Central Nervous System Neoplasms - drug therapy | Central Nervous System Neoplasms - mortality | Cytarabine | Patient outcomes | Central nervous system diseases | Dosage and administration | Lymphomas | Drug therapy, Combination | Methotrexate | Drug therapy | Data analysis | Disease | Monoclonal antibodies | Data collection | Radiation therapy | Patients | Tropical diseases | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2016, Volume 3, Issue 5, pp. e217 - e227
Summary Background Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk... 
Hematology, Oncology and Palliative Medicine | 1ST-LINE TREATMENT | RESPONSE CRITERIA | GUIDELINES | NON-HODGKINS-LYMPHOMA | FOLLOW-UP | CENTRAL-NERVOUS-SYSTEM | WHOLE-BRAIN RADIOTHERAPY | HIGH-DOSE CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Lymphoma, B-Cell - therapy | Middle Aged | Male | Comparative Effectiveness Research | Hyperglycemia - chemically induced | Radiotherapy, Adjuvant - adverse effects | Hematopoietic Stem Cell Transplantation - adverse effects | Lymphoma, B-Cell - diagnostic imaging | Transplantation Conditioning - methods | Rituximab - adverse effects | Induction Chemotherapy - methods | Anemia - chemically induced | Central Nervous System Neoplasms - therapy | Thrombocytopenia - chemically induced | Mucositis - chemically induced | Magnetic Resonance Imaging | Methotrexate - adverse effects | Dexamethasone - therapeutic use | Radiotherapy, Adjuvant - methods | Transplantation, Autologous - adverse effects | Heart Injuries - chemically induced | Italy | Hematopoietic Stem Cell Transplantation - methods | Central Nervous System Neoplasms - mortality | Germany | Thiotepa - adverse effects | Thiotepa - therapeutic use | Thrombosis - chemically induced | Intraocular Lymphoma - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Methotrexate - therapeutic use | Infection - chemically induced | Rituximab - therapeutic use | Stroke - chemically induced | Optic Nerve Neoplasms - diagnostic imaging | Poisoning - epidemiology | Female | Remission Induction - methods | Transplantation Conditioning - adverse effects | Acute Kidney Injury - chemically induced | Neutropenia - chemically induced | Optic Nerve Neoplasms - therapy | Death, Sudden - epidemiology | Lymphoma, B-Cell - mortality | Intraocular Lymphoma - diagnostic imaging | Kaplan-Meier Estimate | Chemical and Drug Induced Liver Injury - epidemiology | Treatment Outcome | United Kingdom | Combined Modality Therapy - adverse effects | Switzerland | Induction Chemotherapy - adverse effects | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Central Nervous System Neoplasms - diagnostic imaging | Denmark | Combined Modality Therapy - methods | Neurotoxicity Syndromes - epidemiology | Gastrointestinal Diseases - chemically induced | Index Medicus
Journal Article
Gastrointestinal Endoscopy, ISSN 0016-5107, 2012, Volume 76, Issue 6, pp. 1142 - 1151
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 11, pp. 1533 - 1542
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2014, Volume 90, Issue 4, pp. 911 - 917
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2013, Volume 87, Issue 5, pp. 1000 - 1006
Purpose To determine the maximum tolerated radiation dose (MTD) of an integrated boost to the tumor subvolume infiltrating vessels, delivered simultaneously... 
Radiology | Hematology, Oncology and Palliative Medicine | CELL LUNG-CANCER | TRIAL | MANAGEMENT | THERAPY | ONCOLOGY | ADENOCARCINOMA | CHEMORADIOTHERAPY | RADIOTHERAPY | CARCINOMA | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | GEMCITABINE | CHEMOTHERAPY | Intestinal Mucosa - radiation effects | Organs at Risk - radiation effects | Chemoradiotherapy - adverse effects | Adenocarcinoma - pathology | Capecitabine | Humans | Middle Aged | Pancreatic Neoplasms - blood supply | Male | Radiotherapy, Intensity-Modulated - adverse effects | Feasibility Studies | Blood Vessels - radiation effects | Neoplasm Staging - methods | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Dose Fractionation | Female | Pancreatic Neoplasms - mortality | Adenocarcinoma - radiotherapy | Chemoradiotherapy - methods | Fluorouracil - analogs & derivatives | Pancreatic Neoplasms - pathology | Radiotherapy, Intensity-Modulated - methods | Induction Chemotherapy - methods | Tumor Burden | Adenocarcinoma - drug therapy | Adenocarcinoma - blood supply | Induction Chemotherapy - adverse effects | Antimetabolites, Antineoplastic - therapeutic use | Gastric Mucosa - radiation effects | Maximum Tolerated Dose | Radiotherapy, Image-Guided - methods | Blood Vessels - drug effects | Duodenum - radiation effects | Aged | Deoxycytidine - analogs & derivatives | Pancreatic Neoplasms - therapy | Sects | Nuclear radiation | Oncology, Experimental | Pancreatic cancer | Research | Cancer | Index Medicus | ULCERS | IMAGES | POSITRON COMPUTED TOMOGRAPHY | CARCINOMAS | FLUORODEOXYGLUCOSE | PANCREAS | RADIOLOGY AND NUCLEAR MEDICINE | RADIATION DOSES | TOXICITY | CT-GUIDED RADIOTHERAPY | PLANNING
Journal Article
British Journal of Cancer, ISSN 0007-0920, 07/2016, Volume 115, Issue 2, pp. 188 - 194
Background: This exploratory analysis evaluated second-line (2L) therapy for metastatic pancreatic cancer in a large phase 3 trial (MPACT). Methods: Patients... 
SURVIVAL | FOLFIRINOX | ONCOLOGY | ADENOCARCINOMA | second line | nab-paclitaxel | gemcitabine | first line | OUTCOMES | MPACT | metastatic pancreatic cancer | Index Medicus
Journal Article
Journal Article